Related Experiment Videos
Phagocytic activity of the tumor associated macrophages in relation to tumor growth: modulation with levamisole
Abstract:
The phagocytic activity of the tumor associate macrophages isolated at different days of the growth of a murine transplantable ascites tumor was assessed by measuring the engulfment of Na2 51CrO4 labeled antibody coated sheep erythrocytes. Binding of the targets by the macrophages was also assessed. It was observed that, excepting the day 3, till day 7 of tumor growth the phagocytic activity of the tumor associated macrophages was very high as compared to that of resident macrophages of normal mice. Augmented target binding by the macrophages was recorded till day 7. Levamisole was observed to augment phagocytosis and target binding by the macrophages but a differential requirement as regard to the dose of Levamisole was noted for modulation of phagocytosis and target binding by the tumor associated macrophages at early and advanced stages of the tumor growth.
Insights
Tumor-associated macrophages exhibit heightened phagocytic activity and target binding until day 7 of ascites tumor growth. Levamisole enhances these functions, with dosage varying by tumor stage.
Area of Science:
- Immunology
- Cancer Biology
- Pharmacology
Background:
- Tumor-associated macrophages (TAMs) play a crucial role in cancer progression.
- Understanding TAMs' phagocytic activity is vital for developing immunotherapies.
- Modulating TAM function could impact tumor growth and treatment efficacy.
Purpose of the Study:
- To assess the phagocytic capacity and target binding of TAMs during ascites tumor development.
- To investigate the effect of Levamisole on TAM phagocytosis and target binding.
- To determine if Levamisole's efficacy varies with tumor progression.
Main Methods:
- Isolation of TAMs at various stages of murine ascites tumor growth.
- Measurement of phagocytosis via engulfment of 51Cr-labeled sheep erythrocytes.
- Assessment of target binding by TAMs.
- Administration of Levamisole to evaluate its immunomodulatory effects.
Main Results:
- TAMs showed significantly higher phagocytic activity and target binding compared to resident macrophages from day 3 to day 7.
- Levamisole demonstrated an ability to augment both phagocytosis and target binding.
- A differential dose requirement for Levamisole was observed for early versus advanced tumor stages.
Conclusions:
- TAMs are highly phagocytic and exhibit enhanced target binding during early to mid-stages of ascites tumor growth.
- Levamisole can enhance TAM functions, suggesting potential therapeutic applications.
- The dose of Levamisole needed to modulate TAMs is dependent on the tumor's stage of development.